Abstract:Introduction: Cancer, the major killer disease of the century requires a multi-pronged approach and among the latest modalities of treatments, Immunotherapy occupies a promising role. Immunotherapy for cancer was first started to be practised in the NIH and cell based immunotherapy for cancer is in practice for the past three decades. ([1, 2]) There are several literatures from various countries on the successful application of cell based Immunotherapies for various solid tumours and haematological malignancies. ([3-8]) Our team's association with immune cells started when I was working on RNA transcriptome analysis to understand the immune system in HIV carriers which in turn required in vitro expansion of human Natural Killer (NK) cells. ([9]) This led to the customization of protocols which has resulted in successful in vitro expansion, activation of NK cells and T cells for Immunotherapy. The purpose of Biotherapy institute of Japan (BIJ) is to support research and clinical application of immune cells like NK cells, γδT cells, αβT cells, Cytotoxic T lymphocytes (CTL) and Dendritic cells (DC) for application as Autologous Immune Enhancement Therapy (AIET) to fight against cancer. AIET using NK cells, CTLs, DCs etc have been administered for more than 5000 patients since 2004 till date by BIJ. Principle of aiet: For AIET using NK cells, the process involves separation of lymphocytes from the peripheral blood of the patient followed by selective NK cell expansion using the expansion kit (BINKIT, BIJ, JAPAN) without feeder layers and then infusion of the expanded-activated NK cells. ([10,11]) As reports suggest that the activity of peripheral blood NK cells are lower in cancer patients compared to normal individuals([12]) and as in vitro expansion of NK cells increases the cytotoxic ability 5 to 10 fold, ([13]) the NK cells are expanded in vivo and then infused to the patient in AIET. We are also working on combination immunotherapy using NK cells and CTLs and also NK cells and peptide pulsed DCs. The principle behind combining NK cells and CTLs is a dual advantage approach combining the innate immune system and adaptive immune system wherein the CTLs will kill the MHC expressing cancer cells while NK cells will kill the MHC non-expressing cancer cells also. ([10]) In case of NK cells and DCs, DCs will in turn activate the CTLs thereby giving rise to the dual advantage mentioned above. We have recently suggested that the AIET using expanded NK cells, particularly in combination with monoclonal antibody drugs, may be very useful tool for cancer immunotherapy. ([14].) Our experience: In our studies in NOG SCID mice, activated NK cells were shown to reduce the size of breast cancer cells (MDA-MB231) ([15]) and the volume of ascites also inhibiting lung metastasis of pleural effusion lymphoma (PEL) cells. ([16]) In a primary lung adenocarcinoma patient where AIET was administered in combination with Hyperthermia, the CEA values decreased from 4.8 ng/ml to 1.6 ng/ml, the SLX decreased from 30 U/ml to 27 U/ml, the IAP reduced from 300 μg/ml to 221 μg/ml along with resolution of the lung lesions in four months. A 55 year old woman treated for invasive ductal carcinoma of breast presented with metastasis to the lungs. She was then treated with trastuzumab in combination with multiple injections of activated natural killer (NK) cells (at two week intervals) following which the tumor markers decreased. Progression free survival was 10 months. ([11]) Fifty-two patients with advanced cancers in organs like lung, breast, colon, prostate, liver, kidney, ovary etc, refractory to conventional therapy when treated with a combination of hyperthermia and NK cell-and CTL-based immune cell therapy with low-dose chemotherapy, in 18 of 52 patients, objective responses was observed including one complete response (CR) and 17 partial responses (PR) evaluated according to to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. Sixteen patients had stable disease (SD), whereas 18 had progressive disease (PD). Disease control rate was 66% including CR, PR and SD. After treatment for six months, the objective responses and disease control rate were 25% and 52%, respectively. There were no adverse effects in any of these patients. ([17].) Conclusion: Cancer has to be tackled with a multipronged approach and combining NK cell and CTL cell based AIET with conventional modalities of treatments such as Surgery, Chemotherapy and Radiotherapy as well as other modalities like Hyperthermia, Proton Beam therapy and low dose chemotherapy is effective even in advanced cancers which are refractory to conventional therapeutic modalities.

Study on the TIL and NK of IL-2 Injected Via Pelvic Retroperitoneal Space in Gynecological Cancer Patient

THE AFFECION ON THE TREATMENT TO HEPATIC CANCER BY INJECTION OF CHEMICALS WITH IL-2 VIA EMBEDDED SUBCUTANEOUS CHEMATHERAPUTIC PUMP

[A randomized study of intensity-modulated radiation therapy versus three dimensional conformal radiation therapy for pelvic radiation in patients of post-operative treatment with gynecologic malignant tumor]

Clinical study on immunotherapy of ovarian cancer with tumor infiltrating lymphocytes]

Tumor-infiltrating CD8+ and FOXP3+ Lymphocytes Before and after Neoadjuvant Chemotherapy in Cervical Cancer

Interleukin-2 Administration Alters the Cd4(+)Foxp3(+) T-Cell Pool and Tumor Trafficking in Patients with Ovarian Carcinoma

Application Of Ct-Guided Ad-P53 Intratumoral Injection For Recurrent And Metastatic Gynecologic Cancer Patients Who Received Chemoradiation Therapy

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial

Anti-Tumor Activity of Expanded PBMC-Derived NK Cells by Feeder-Free Protocol in Ovarian Cancer.

Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study

Animal Experiments of Immunotherapy with Ovarian Tumor Vaccine During Lymphopenia Induced by Chemotherapy

Cytotoxic Activity of IL-15 Gene Modified-Nk Cells Against Primary Ovarian Cancer Cells

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice.

[Subcutaneous Transplantation of Microencapsulated Chinese Hamster Ovary (CHO) Cells/pcdna 3.1/Mil-12 and Subcutaneous Transplantation of Microencapsulated CHO/pcDNA3.1/mIL-12 Combined with 5-Fluoro-uracil in Treatment of Tumor-Burdened Mice].

Therapeutic Effect of Tumor Infiltrating Lymphocyte Plus Interleukin-2 Intrapleural Injection on Advanced Cancer Patients with Malignant Pleural Effusion

Autologous Immune Enhancement Therapy for Cancer - Our experience since 2004

Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity

Extended Field or Pelvic Intensity-Modulated Radiotherapy with Concurrent Cisplatin Chemotherapy for the Treatment of Post-Surgery Multiple Pelvic Lymph Node Metastases in Cervical Cancer Patients: a Randomized, Multi-Center Phase II Clinical Trial

Prophylactic Use of Low-Dose Interleukin-2 and the Clinical Outcomes of Hematopoietic Stem Cell Transplantation: A Randomized Study